AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Thrombotic Thrombocytopenic Purpura

Recent research efforts aimed at curing Thrombotic Thrombocytopenic Purpura.

Last updated

Thrombotic Thrombocytopenic Purpura

Overview

Thrombotic thrombocytopenic purpura (TTP) is a rare, life-threatening disorder in which tiny platelet-rich clots form throughout small blood vessels. These clots consume platelets, damage red blood cells, and can injure the brain, heart, kidneys, and other organs. TTP is usually immune-mediated (iTTP), in which antibodies block or accelerate removal of the clot-regulating enzyme ADAMTS13; less commonly it is congenital (cTTP), caused by inherited disease-causing variants in the ADAMTS13 gene. Without prompt treatment, acute TTP can be fatal, but modern care has greatly improved survival. 2025 ISTH management guideline Recombinant ADAMTS13 in cTTP

For acute iTTP, standard care combines therapeutic plasma exchange—removing antibody-containing plasma and replacing it with donor plasma—with corticosteroids, immune suppression such as rituximab, and caplacizumab, a drug that temporarily prevents von Willebrand factor from binding platelets. In cTTP, the central problem is missing ADAMTS13 rather than autoimmunity; regular or on-demand replacement with recombinant ADAMTS13 is now an approved targeted option in the United States for children and adults. 2025 ISTH management guideline FDA approval of Adzynma

Scope of Recent Research (2020–present)

Research since 2020 has been active but is pursuing different goals for the two forms of TTP: durable enzyme replacement and eventual genetic correction for cTTP, versus lasting elimination of the anti-ADAMTS13 autoimmune response for iTTP. The field has achieved a major disease-targeted advance with recombinant ADAMTS13 for cTTP, while iTTP research is testing ways to reduce treatment burden, prevent relapse, and eradicate the antibody-producing immune cells. A one-time curative therapy is not yet available for either form. Recombinant ADAMTS13 phase 3 trial 2026 treatment update

Major Breakthroughs and Emerging Therapies

Enzyme replacement for congenital TTP. The most consequential recent advance is recombinant ADAMTS13, apadamtase alfa (Adzynma), which replaces the enzyme missing in cTTP. In the randomized phase 3 crossover trial, 48 participants received recombinant ADAMTS13 or plasma-based standard therapy: no acute TTP event occurred during recombinant-ADAMTS13 prophylaxis, compared with one during standard therapy; recombinant treatment also produced mean peak ADAMTS13 activity near normal levels and fewer treatment-related adverse events. This is not a genetic cure because ongoing infusions are required, but it is a mechanism-based replacement therapy that can reduce dependence on donor plasma. Recombinant ADAMTS13 phase 3 trial FDA approval of Adzynma

Improving treatment of immune TTP with recombinant ADAMTS13. In iTTP, autoantibodies create severe ADAMTS13 deficiency, so simply giving standard enzyme replacement may not always work. A 2024 report described a critically ill person with treatment-refractory iTTP who recovered after recombinant ADAMTS13; laboratory studies suggested the administered enzyme formed immune complexes with the autoantibodies, potentially saturating them and aiding clearance. This is an important proof-of-concept and not evidence of a broadly effective cure, since it was a single-patient clinical report. Recombinant ADAMTS13 for iTTP

Autoantibody-resistant ADAMTS13 proteins. Researchers are engineering “muteins”—altered versions of ADAMTS13 designed to retain the ability to cut von Willebrand factor while avoiding the antibody-binding regions targeted in iTTP. In 2024, investigators reported GC1126A, a modified, Fc-fused ADAMTS13 candidate that retained activity in the presence of several inhibitory anti-ADAMTS13 antibodies and showed a longer circulating half-life in preclinical testing. Such molecules could eventually provide enzyme activity even during active iTTP, but they remain preclinical. GC1126A ADAMTS13 mutein study

More durable immune reset for iTTP. Rituximab removes CD20-positive B cells but does not directly remove long-lived plasma cells that can continue making autoantibodies. Daratumumab, an anti-CD38 antibody used in myeloma, targets plasma cells; a 2021 two-patient report found eradication of persistent inhibitory antibodies and restoration of normal ADAMTS13 activity in highly difficult iTTP cases. A subsequent French nationwide experience examined daratumumab in multiresistant iTTP, reflecting growing interest in plasma-cell-directed treatment for patients who remain antibody-positive despite conventional B-cell therapy. These approaches may produce long remissions, but they are not yet proven curative and can carry substantial immune-suppression risks. Daratumumab case report French nationwide daratumumab study

Clinical Trials and Experimental Approaches

The pivotal completed phase 3 trial of recombinant ADAMTS13, NCT03393975, was sponsored by Takeda Development Center Americas and Baxalta Innovations and compared prophylactic recombinant ADAMTS13 with plasma-based therapy in cTTP. Its interim results supported U.S. approval in November 2023, and the final analysis reported lower modeled rates of subacute TTP events during recombinant-ADAMTS13 prophylaxis than during plasma-based therapy. A phase 3b continuation study, NCT04683003, has followed longer-term use. Recombinant ADAMTS13 phase 3 trial Final phase 3 analysis

For iTTP, Sanofi’s MAYARI study, NCT05468320, tested caplacizumab plus immunosuppressive therapy without first-line plasma exchange. The completed, open-label multicenter study enrolled 51 adults in 11 countries; its sponsor-facing public summary reports that most participants improved and that the regimen was generally tolerated. This strategy is not intended to cure the autoimmune disease, but it could make emergency treatment less invasive if validated against appropriate comparators. MAYARI trial summary MAYARI CTIS record

A new Takeda-sponsored observational early-access study, NCT07429942, is not yet recruiting as of its May 29, 2026 update and will document outcomes among people with cTTP who received recombinant ADAMTS13 through an early-access program. It is designed to gather real-world evidence on treatment patterns, platelet measures, and clinical outcomes rather than to test a one-time curative intervention. NCT07429942

Methodologies and Scientific Approaches

TTP research relies on measuring ADAMTS13 activity, anti-ADAMTS13 antibody levels, platelet count, hemolysis markers, and clinical thrombotic events. In iTTP, these biomarkers help distinguish ongoing autoimmunity from clinical remission and identify people whose persistently low ADAMTS13 activity may justify preemptive immune therapy. Researchers also use biochemical assays of von Willebrand-factor cleavage and antibody-binding experiments to screen engineered ADAMTS13 variants. Mechanism of ADAMTS13 deficiency in iTTP GC1126A ADAMTS13 mutein study

Preclinical delivery approaches include recombinant enzyme infusion and platelet-targeted ADAMTS13 replacement, in which engineered platelets carry ADAMTS13 toward forming clots. The latter approach is experimental but aims to concentrate the enzyme where harmful clotting occurs, potentially reducing the amount of systemic treatment needed. Platelet-targeted ADAMTS13 replacement

Leading Institutions and Funding

Takeda and its predecessor Baxalta sponsored the multinational recombinant-ADAMTS13 phase 3 program, which involved 34 sites across Europe, the United States, the United Kingdom, and Japan, including centers such as Duke University Medical Center, Institut Imagine, and the French National Reference Center for Thrombotic Microangiopathies. These multinational networks are essential because cTTP is ultra-rare and no single center can readily recruit large trials. Recombinant ADAMTS13 phase 3 trial

Public funding continues to support foundational work. In June 2026, the U.S. National Heart, Lung, and Blood Institute awarded Beth Israel Deaconess Medical Center an R01 grant of $1,626,320 for “ADAMTS13 in Human Health and Disease,” including studies of iTTP genetics and proteomics. Canadian Blood Services, funded by Health Canada and provincial and territorial health ministries, supported platelet-targeted ADAMTS13 research. NIH award R01HL180838 Platelet-targeted ADAMTS13 replacement

Strengths, Limitations, and Challenges

The strongest progress is that treatment now directly addresses the underlying ADAMTS13 defect in cTTP, rather than relying exclusively on donor plasma. However, recombinant ADAMTS13 remains replacement therapy, not a permanent correction of the inherited gene defect. Safety monitoring is also evolving: on September 23, 2026, the FDA announced a new boxed warning after reports of neutralizing antibodies that can block Adzynma’s effect, underscoring the need for continued activity monitoring and post-marketing surveillance. FDA safety communication on Adzynma

For iTTP, caplacizumab and immune suppression have reduced acute harm, but they do not reliably remove the long-term tendency to form anti-ADAMTS13 antibodies. Evidence for recombinant ADAMTS13 in iTTP and for plasma-cell-directed therapies is currently limited to small cohorts or case reports, and deeper immune suppression may raise infection risk, reduce vaccine responses, and be difficult to access. The central unanswered question is how to selectively and durably eliminate pathogenic anti-ADAMTS13 immunity without broadly compromising normal immune protection. Recombinant ADAMTS13 for iTTP Daratumumab case report 2026 treatment update

Outlook and Future Directions

As of September 29, 2026, cTTP is closer to sustained disease control than ever before because recombinant ADAMTS13 can replace the missing enzyme, but it is not yet cured; a true cure would likely require safe, durable correction of ADAMTS13 expression through gene-based therapy. For iTTP, the most important milestones will be larger prospective studies of recombinant or antibody-resistant ADAMTS13, confirmation that plasma-cell-directed therapy can produce durable treatment-free remission, and biomarker-guided strategies that prevent relapse before organ injury occurs. The realistic near-term goal is not a one-time cure, but safer, less burdensome, durable remission. 2026 treatment update 2025 ISTH management guideline

References

Don't see your disease? Request a report